Liraglutide
Brand: Victoza (T2DM) / Saxenda (Weight loss)
Antidiabetic
GLP-1 receptor agonist
Pharmacokinetics
| Half-life | 13 hours |
| Tmax | 11 h |
| Bioavailability | 55 % (approx) |
| Protein Binding | 98 % |
| Volume of Distribution | 0.013 L/kg (approx) |
| Clearance Route | other |
| Active Metabolites | no |
| Notes | half-life ~13 h supports once-daily dosing; not CYP metabolized. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Nausea, vomiting, diarrhea/constipation, decreased appetite, injection-site reactions
Contraindications:
Personal or family history of medullary thyroid carcinoma, MEN2
Precautions:
Pancreatitis risk (stop if suspected); hypoglycemia mainly with insulin/sulfonylureas; may delay gastric emptying and affect oral drug absorption